Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(28.6%)

Phase 3

2(28.6%)

Phase 1

1(14.3%)

Phase 2

1(14.3%)

Phase 4

1(14.3%)

7Total

N/A(2)

Phase 3(2)

Phase 1(1)

Phase 2(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT06403631Completed

Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis

Role: collaborator

NCT06396364Not ApplicableCompleted

Cryotherapy Reduces Time to Surgery and Local Complication in Patients With Ankle Fractures

Role: lead

NCT06074965Not ApplicableCompleted

Impact of Two Medtronic Infusion Sets on Lipohypertrophy in Type 1 Diabetes (T1DM) Patients Thought to Have LH

Role: lead

NCT01437969Completed

Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.

Role: collaborator

NCT02311244Completed

The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes

Role: collaborator

NCT03561389Unknown

iFR-guided Revascularization in STEMI

Role: lead

NCT03827577Phase 3Unknown

OMEGA, Local Ablative Therapy in Oligometastatic NSCLC

Role: collaborator

NCT02869906Unknown

Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Non Culprit Lesions in Patients With ST-segment Elevation Myocardial Infarction

Role: lead

NCT02702739Phase 4Completed

Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients

Role: lead

NCT01784549Phase 2Unknown

Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease

Role: collaborator

NCT02025842Completed

Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma

Role: lead

NCT01342003Completed

HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b

Role: lead

NCT01242306Phase 1Completed

Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions

Role: lead

NCT01160900Phase 3Unknown

FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.

Role: lead

All 14 trials loaded